Pfizer-BioNTech has begun testing a third dose of its COVID-19 vaccine in a small group of people. The vaccine is currently authorized in several countries in a two-dose regimen, given 21 days apart, and has proven in studies to be about 95% effective in protecting against COVID-19 disease. But as new (and more infectious) genetic variants of the COVID-19 virus start circulating—so far, scientists have identified three major strains, first found in the U.K., South Africa, and Brazil, respectively—questions about how well authorized vaccines can still thwart the virus have become more urgent. Pfizer-BioNTech have already done studies testing blood serum from people vaccinated with their original shot against some of these variants, and found that the immune response triggered by the two doses is still quite protective.

Topics:  u.k    b.1.1   b.1.351    brazilian   p1     ldquo;so   mikael dolsten   phase   it&rsquo   covfid-19   u.s food   drug administration   covid-19   u.k   south africa   brazil   pfizer-biontech   south african   pfizer   test   dose   virus   variant   people   original   variants   referred   vaccinated   studies   levels   trial   plans   current   received   give   boost   strains   regimen   authorized   genetic   months   vaccines   data   produced   researchers   immune   antibodies   change   level   similar   mrna   part   protection   targeting   production   process   

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More News